Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,012 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Can the reliance of hormone receptor assays of surgical specimens be explained by the fluctuation of estrogen receptor, progesterone receptor, and HER-2 protein expression in tumor samples of premenopausal breast cancer patients?
Alimonti A, Ferretti G, Cognetti F. Alimonti A, et al. Among authors: ferretti g. J Clin Oncol. 2005 Dec 1;23(34):8918; author reply 8918-9. doi: 10.1200/JCO.2005.03.9024. J Clin Oncol. 2005. PMID: 16314657 No abstract available.
Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
Papaldo P, Lopez M, Cortesi E, Cammilluzzi E, Antimi M, Terzoli E, Lepidini G, Vici P, Barone C, Ferretti G, Di Cosimo S, Nistico C, Carlini P, Conti F, Di Lauro L, Botti C, Vitucci C, Fabi A, Giannarelli D, Marolla P. Papaldo P, et al. Among authors: ferretti g. J Clin Oncol. 2003 Sep 15;21(18):3462-8. doi: 10.1200/JCO.2003.03.034. J Clin Oncol. 2003. PMID: 12972521 Clinical Trial.
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?
Papaldo P, Ferretti G, Di Cosimo S, Giannarelli D, Marolla P, Lopez M, Cortesi E, Antimi M, Terzoli E, Carlini P, Vici P, Botti C, Di Lauro L, Naso G, Nisticò C, Mottolese M, Di Filippo F, Ruggeri EM, Ceribelli A, Cognetti F. Papaldo P, et al. Among authors: ferretti g. J Clin Oncol. 2006 Jul 1;24(19):3048-55. doi: 10.1200/JCO.2005.02.9488. Epub 2006 Jun 12. J Clin Oncol. 2006. PMID: 16769988 Clinical Trial.
Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?
Di Cosimo S, Ferretti G, Papaldo P, Carlini P, Fabi A, Ruggeri EM, Alimonti A, Nardoni C, Cognetti F. Di Cosimo S, et al. Among authors: ferretti g. Ann Oncol. 2005 Jul;16(7):1209-10. doi: 10.1093/annonc/mdi201. Epub 2005 Apr 27. Ann Oncol. 2005. PMID: 15857847 Free article. Clinical Trial. No abstract available.
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, Salesi N, Giannarelli D, Alimonti A, Di Cocco B, D'Agosto G, Bordignon V, Trento E, Cognetti F. Ferretti G, et al. Oncology. 2005;69(1):35-43. doi: 10.1159/000087286. Epub 2005 Aug 2. Oncology. 2005. PMID: 16088233 Clinical Trial.
Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?
Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandala M, Papaldo P, Nistico C, Fabi A, Cuppone F, Gelibter A, Terzoli E, Cognetti F. Ferretti G, et al. J Clin Oncol. 2005 Oct 1;23(28):7248-50; author reply 7250. doi: 10.1200/JCO.2005.01.7897. J Clin Oncol. 2005. PMID: 16192623 No abstract available.
1,012 results